Skip to main content
PMC home page
Redox Report : Communications in Free Radical Research logoLink to Redox Report : Communications in Free Radical Research
. 2023 Aug 29;28(1):2251234. doi: 10.1080/13510002.2023.2251234

Melatonin suppresses Akt/mTOR/S6K activity, induces cell apoptosis, and synergistically inhibits cell growth with sunitinib in renal carcinoma cells via reversing Warburg effect

Kai-Hua Xue a,*, Yi-Fan Jiang a,*, Ji-Yu Bai a, Di-Ze Zhang a, Yu-Hang Chen a, Jian-Bin Ma a, Zhi-Jing Zhu a, Xinyang Wang a,b,c, Peng Guo a,b,c,CONTACT
PMCID: PMC10472857  PMID: 37642220

ABSTRACT

Background

Metabolic alteration drives renal cell carcinoma (RCC) development, while the impact of melatonin (MLT), a neurohormone secreted during darkness, on RCC cell growth and underlying mechanisms remains unclear.

Methods

We detected concentration of metabolites through metabolomic analyses using UPLC-MS/MS, and the oxygen consumption rate was determined using the Seahorse Extracellular Flux analyzer.

Results

We observed that MLT effectively inhibited RCC cell growth both in vitro and in vivo. Additionally, MLT increased ROS levels, suppressed antioxidant enzyme activity, and induced apoptosis. Furthermore, MLT treatment upregulated key TCA cycle metabolites while reducing aerobic glycolysis products, leading to higher oxygen consumption rate, ATP production, and membrane potential. Moreover, MLT treatment suppressed phosphorylation of Akt, mTOR, and p70 S6 Kinase as well as the expression of HIF-1α/VEGFA in RCC cells; these effects were reversed by NAC (ROS inhibitors). Conversely, MLT synergistically inhibited cell growth with sunitinib and counteracted the Warburg effect induced by sunitinib in RCC cells.

Conclusions

In conclusion, our results indicate that MLT treatment reverses the Warburg effect and promotes intracellular ROS production, which leads to the suppression of Akt/mTOR/S6K signaling pathway, induction of cell apoptosis, and synergistically inhibition of cell growth with sunitinib in RCC cells. Overall, this study provides new insights into the mechanisms underlying anti-tumor effect of MLT in RCC cells, and suggests that MLT might be a promising therapeutic for RCC.

KEYWORDS: Melatonin, renal cell carcinoma, mitochondria, ROS, cell apoptosis, Akt/mTOR/S6K, HIF-1 α, sunitinib

Introduction

In the 2022 analysis of US cancer statistics, 79,000 cases of kidney cancer were diagnosed [1]. Renal clear cell carcinoma (ccRCC) is still the most common phenotype of renal cell carcinoma (RCC) and the main cause of morbidity and mortality [1,2]. Although many effective treatments have been used, the survival rate of patients with RCC has not been effectively improved [2]. Dominant therapies are based on preventing or reversing the course of chemoresistance, which plays a key role in the treatment of RCC. Interestingly, in recent years RCC has been revealed to share a recurrent pattern of mutations to metabolic genes, including VHL, MTOR, ELOC, TSC1/2, FH, SDH, and mitochondrial DNA through the leveraging high-throughput technologies to measure small-molecule metabolites [3,4], indicating that RCC could be a mitochondrial metabolism-related disease, in which metabolic reprogramming plays a key role in tumorigenesis and metastasis [5]. Therefore, exploring new targets in mitochondrial metabolic pathways could be essential for applying new therapy in RCC treatment.

Mitochondria plays a much more significant role in cancer metabolism than previously thought [6], which is the major source of ATP, reactive oxygen species (ROS), and biosynthetic metabolites [7] in cells. In addition, mitochondria also serves as a signaling center in multiple cellular processes including proliferation, differentiation, autophagy, and apoptosis via activating corresponding signaling pathways [8,9]. Mitochondria in cancer cells are characterized by ROS overproduction, which promotes cancer development by inducing genomic instability, modifying gene expression, and participating in signaling pathways [10,11]. On the other hand, the antioxidant enzyme superoxide dismutase (SOD), catalase (CAT), and nonenzymes such as glutathione (GSH) can remove ROS in cells, and there is a negative correlation with ROS [12]. Hence, antioxidant enzymes and mitochondria metabolic homeostasis in cancer cells can be modulated to restrain the growth of tumor cells.

Melatonin (MLT) is the primary neurohormone secreted during the dark hours at night by the vertebrate pineal gland. MLT performs a variety of physiological functions by binding to membrane MT1 and MT2 receptors, while triggering downstream signaling cascades activation [13]. Studies have shown that MLT in mitochondria is 100 times more than that in the cytoplasm, which provides a crucial role in balancing ROS balance [14]. In particular, the energy source of tumor cells is in the process of aerobic glycolysis (Warburg effect), during which substances in aerobic respiration are inhibited, and the accumulation of lactic acid and increased PH provide a more comfortable environment for the proliferation and metastasis of tumor cells [15]. Studies have reported that MLT can metabolize energy in tumor cells, reversing the Warburg effect and thereby inhibiting cancer cell growth [16,17]. Moreover, MLT is a proven anticancer drug that inhibits tumor growth by inhibiting tumor cell proliferation, maintaining gene stability, promoting tumor cell apoptosis and autophagy [16,18–21]. RCC is sometimes termed as a ‘metabolic disease’. The majority of metabolic reprogramming in RCC is caused by the inactivation of VHL gene and activation of the Ras-PI3K-AKT-mTOR pathway. Hypoxia-inducible factor (HIF) and Myc are other important players in the metabolic reprogramming of RCC. All types of RCC are associated with reprogramming of glucose and fatty acid metabolism and the tricarboxylic acid (TCA) cycle [22]. However, the effects of MLT on RCC cell metabolic reprogramming and cell growth remain unknown.

Sunitinib combined with Avelumab and Nivolumab has become the mainstay of treatment for RCC [23,24], but its resistance is also significant [25]. In previous studies, it was found that the resistance of sunitinib were often accompanied by an increase in tumor cell glycolysis, indicating an enhanced Warburg effect [26,27]. Therefore, we wondered whether MLT could attenuate the resistance of sunitinib caused by increased glycolysis.

In this study, we investigated whether MLT treatment can inhibit the growth of 786-O, 769-P and SW839 RCC cells in vitro and in vivo. Moreover, we detected the metabolomic change, mitochondrial function, and antioxidant enzyme activity in RCC cells after MLT treatment, to determine whether MLT can reprogram cell metabolism, switching from glycolysis to oxidative phosphorylation (OXPHOS), by regulating mitochondrial respiration and producing more ROS. Whether MLT inhibits Akt/mTOR/S6K/HIF-1ɑ/VEGF pathway and induces cell apoptosis via ROS was determined as well. We also explored whether the combination of MLT with sunitinib could reduce sunitinib resistance via reversing the Warburg effect. This study may provide a new strategy for RCC therapy focusing on metabolism reprogramming.

Materials and methods

Cell culture

The RCC cells lines 786-O, 769-P, SW839 and Human Renal Cortex Proximal Tubule Epithelial Cells HK-2 were purchased from the Cell Bank of Type Culture Collection of Chinese Academy of Sciences (Shanghai, China). 786-O, 769-P and SW839 were cultured in RPMI 1640 medium (Sigma-Aldrich, Wisconsin, USA), and HK-2 cells were maintained in Ham's/F-12 medium (Procell, Wuhan, China), containing 10% fetal bovine serum and 1% penicillin/streptomycin (Invitrogen Co., Carlsbad, CA, USA). All cells were cultured at 37°C in a saturated aqueous atmosphere of 5% CO2 and collected at the peak of the logarithmic growth phase for experiments.

Reagents and antibodies

Melatonin (MLT) (T1659), Sunitinib (T0374L), 3-TYP (T4108) and N-Acetylcarnosine (NAC) (TP1088) were purchased from Topscience (Shanghai, China), and dissolved in DMSO. 2-(4-Amidinophenyl)-6-indolecarbamidine dihydrochloride (DAPI) was from Servicebio (Wuhan, China). Antibodies against SIRT3 (2627), mTOR (2983), Phospho-mTOR (Ser2448) (5536), Phospho-p70 S6 Kinase (Thr389/Ser371) (9208,9234), Akt (4691), Phospho-Akt (Ser473) (4046), Cleaved-PARP (5625), Caspase3 (9662), Cleaved-caspase3 (9664), β-actin (3700) were purchased from Cell Signaling Technology (Beverly, MA, USA). Antibodies against MnSOD (ab68155), MnSOD (acetyl K122) (ab214675), Bax (ab32503), Bcl2 (ab32124) were purchased from Abcam (Cambridge, UK). Antibodies against HIF-1ɑ (NB100-105) were purchased from Novus Biologicals. Antibodies against VEGF (SC-7269) were purchased from Santa Cruz Biotechnology.

MTT assays

Cell viability was evaluated using the MTT assay. At the end of incubation, both cell types (2500 cells per well) were incubated with MTT (5 mg/ml) (Abcam) for an additional 2 h. Then the crystal formazan was dissolved in dimethyl sulfoxide (DMSO; 150 µl/well; ECHO Chemical Co. Ltd., Shanghai), and 96-well microplate reader (Bio-Rad, Hercules, USA) was used to measure the absorbance at the wavelength of 490 nm. The morphological changes in the cells were observed under a microscope.

Colony formation assay

786-O, 769-P and SW839 RCC cells in logarithmic growth phase were seeded in each well of a 6-well plate (1000 cells/well) and cultured in 1640 medium supplemented with 10% fetal bovine serum in an incubator with 5% CO2 at 37°C. 11 days after inoculation, when colonies formed, the medium was discarded, the colonies were washed three times with PBS, fixed with 4% paraformaldehyde for 15 min, stained with crystal violet for 15 min, and the staining solution was slowly washed with running water. After the plates were air-dried, the number of colonies was determined.

Animal experiments

Female BALB/c mice, four weeks old, were obtained from Shanghai Experimental Animal Center of Chinese Academic of Sciences (Shanghai, China) and housed in Animal Room (SPF) of Xi'an Jiao Tong University according to standard conditions. All animal experiments were approved by the ethics committee of Xi'an Jiao Tong University (Xi'an, China) and complied with the legal requirements and national guidelines for the care and maintenance of experimental animals. After one week of adaptation, 5 × 106 786-O cells in 100 μL of PBS were injected subcutaneously on the right side of each mouse. Tumor size was measured every other day by means of a Vernier caliper, and tumor volume was estimated according to the following formula: tumor volume = (length × width2)/2. The body weight was measured with an electronic balance every other day. When tumors reached an average volume of 100 mm3 (approximately 10–12 days post injection), the mice were randomly divided into two groups: Mice were administered with 0.9% DMSO as a control group or administered with MLT (25 mg/kg) through intraperitoneal (i.p.) injection every other day in the evening (18:00–20:00). Twelve days after treatment, all the mice were sacrificed, and the entire tumor was collected and weighed. During this period, the body weight and tumor size of each animal were monitored as described above.

Western blotting analysis

The expression levels of related proteins were detected by Western blotting. Briefly, cell samples were collected 24 h after MLT treatment and dissolved in 1 × radioimmunoprecipitation buffer with 1% phenylmethylsulfonyl on ice for 20 min. Quantification was performed with a bisphenol acid assay kit (Beyotime, Shanghai, China). After boiling for 10 min at 100°C, aliquots of 20 μg protein were separated by electrophoresis on 10% or 12% sodium dodecyl sulphate-polyacrylamide gels, transferred to polyvinylidene difluoride membranes, and then blocked with 5% skim milk for 1 h at room temperature. The cells were incubated with primary antibody on a shaker (4°C overnight). After washing three times with TBST and incubating with the corresponding secondary antibody for 2 h at room temperature, immunoblots on the membranes were visualized using an enhanced chemiluminescence detection kit (Millipore, Burlington, MA, USA). β-actin was used as a loading control for total homogenates; MnSOD was used as a loading control for isolated mitochondria. Densitometry was performed using ImageJ 1.52k software.

Apoptosis assay

The apoptotic ratio of cells treated with MLT were analyzed by flowcytometry (BD FACScan flow cytometer, BD Biosciences). Cells were implanted into 6-well plates at a density of 4 × 105 cells/well. After Mel for 24 h, the cells were washed twice with precooled PBS, and then collected in 1.5 ml tubes and centrifuged at 500 × g (4°C) for 5 min. Subsequently, the cells were resuspended in 100 µl of binding buffer, and mixed with 4 µl of Annexin V-FITC and 4 µl of propidium iodide (PI) for 15 min. After that, 400 μl of binding buffer was added for dilution and flow cytometry was performed to measure the proportions of apoptotic cells. For inhibition experiments, cells were preincubated with 5 mM NAC (ROS scavenger) for 1 h, washed three times with PBS after MLT and incubated for 24 h. In addition, fluorescence intensity was assessed by the same method as above.

Mitochondrial SIRT3, MnSOD and Ack122 Mn-SOD assay

Mitochondrial extracts were prepared using the Cell Mitochondria Isolation kit (Beyotime Biotechnology) according to manufacturer’s instructions after the 786-O cells treated with MLT and 3-TYP for 24 h. Purity of the mitochondrial fraction was assessed by MnSOD (a mitochondrial marker). The levels of SIRT3 and Ack122 Mn-SOD in mitochondrial protein were subsequently detected via Western blotting analysis.

Measurement of ROS concentration

2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA) were from KeyGen BioTECH (Nanjing, China). DCFH-DA is a non-fluorescent cell permeable compound, which can be hydrolyzed by intracellular endogenous esterase, and its products are oxidized by intracellular ROS and finally converted into DCF with fluorescent signal. Because DCF cannot freely pass through the cell membrane, its fluorescence intensity can be used to reflect the amount of ROS produced in the cell. The specific method was to wait for 24 h after the cells were treated with MLT, and incubate with serum-free medium containing 10 μM DCHF-Da for 30 min in the dark. After treatment, the fluorescence intensity of different groups of cells was photographed by fluorescence microscope with the same exposure intensity, and then detected by flow cytometry immediately to prevent the fluorescence intensity from weakening and disappearing.

Measurement of antioxidant enzyme activities

Briefly, cell samples at 24 h after MLT treatment were collected and lysed in 1 × radioimmunoprecipitation assay buffer for 20 min on ice. The supernatant was collected. After been quantified by a bicinchoninic acid assay kit (Beyotime), the levels of GSH-Px, SOD, GSH, and CAT in cells were measured with antioxidant kits (Jiancheng Bioengineering Institute, Nanjing, China). Absorbance at the corresponding wavelength was determined by a microplate reader (Bio-Rad, Hercules, USA).

Metabolomic analysis

After six hours of treatment with MLT, the 786-O cells were flash-frozen in liquid nitrogen. The TCA cycle metabolites, acetyl-CoA, citrate, isocitrate, succinate, pyruvate, and lactate in the samples, were quantitatively determined by ultraperformance liquid chromatography, in combination with triple quadrupole mass spectrometry (UPLC-MS/MS) (Shanghai Applied Protein Technology Co., Ltd). The data acquisition, principal component analysis, heatmap, and pathway impact analysis were performed by Shanghai Applied Protein Technology Co., Ltd.

Mitochondrial respiration

The oxygen consumption rate (OCR) was determined using the Seahorse Extracellular.

Flux XF-96 analyzer (Seahorse Bioscience, N. Billerica, MA, USA). Cells were seeded in XF 96-well cell culture microplates (Seahorse Bioscience) at a density of 1 × 104 /well and incubated overnight at 37°C with 5% CO2. After 24 h, the medium in the 96-well plate was carefully aspirated and then MLT was added at various concentrations (2, 4 mM) overnight. Prior to Base Medium (102353-100, Seahorse Bioscience) containing 10 mM glucose, 5 mM pyruvate, and 2 mM glutamine, and the cells were equilibrated for 1 h at 37°C without CO2. Oxygen concentration in media was measured under basal conditions and after sequential addition of compounds as indicated in corresponding figure legends. Concentration of inhibitors used was as follows: Oligomycin A (1.5 μM), Fccp (2.0 μM), and a mixture of rotenone (500 nM) and antimycin A (500 nM). A minimum of four wells were utilized per condition to calculate OCR and it was normalized by the number of cells.

Measurement of mitochondrial membrane potential

The increase of mitochondrial membrane potential (ΔΨm) was monitored with fluorescent probe JC-1 (Beyotime). 786-O,769-P and SW839 cells were treated with different concentrations of MLT (2,4 mM) for 24 h, and then incubated with JC-1 (10 μM, final concentration) in the dark at 37°C for 20 min. Finally, after washing with JC-1 buffer, cells were collected and analyzed by flow cytometry (BD Biosciences). Then, the fluorescence intensity of different groups of cells was observed immediately with a fluorescence microscope.

Cell and tumor tissue ATP production measurement

The ATP content in 786-O,769-P and SW839 cells was measured using a luciferase-based luminescence-enhanced ATP analysis kit (Beyotime). The cells were washed twice with ice-cold PBS, collected in 100 μL of ice-cold ATP release buffer, and centrifuged at 12,000 × g for 5 min at 4°C. Subsequently, the isolated mitochondria (with a protein concentration of 1 mg/mL) were incubated in 0.5 mL of respiratory buffer containing 2.5 mM succinate, 2.5 mM malate, and 2.5 mM ADP for 10 min. The ATP content in cell lysates and mitochondrial suspensions were then measured using a SpectraMax Paradigm multi-mode microplate reader (Molecular Devices). A portion of the tumor tissue was added to 150 μL of lysate per 20 mg and lysed thoroughly by ultrasound. After centrifugation, the supernatant was taken in the same procedure as above.

Measurement of pyruvate activities

Briefly, cell samples at 24 h after MLT treatment were collected and lysed in 1 × radioimmunoprecipitation assay buffer for 20 min on ice. The supernatant was collected. After been quantified by a bicinchoninic acid assay kit (Beyotime), the levels of pyruvate in cells were measured with antioxidant kits (Jiancheng Bioengineering Institute, Nanjing, China). Absorbance at the corresponding wavelength was determined by a microplate reader (Bio-Rad, Hercules, USA).

Immunohistochemistry (IHC) analysis

Ki-67 and p-Akt antibodies were purchased from Servicebio (Wuhan, China) to analyze the expression level of these two proteins. Control and MLT-treated tumor tissues were fixed with 4% PFA overnight at 4°C. Then, the tissues were washed four times with precooled PBS, gently mounted in optimum cutting temperature (OCT) embedding compound, frozen at −20°C, and then transferred to a −80°C freezer. Tissue sections were prepared at a thickness of 5 µm and placed on histological slides. The sections were fixed in acetone for 12 min and then washed four times in PBS. Then, the sections were blocked and permeabilized with blocking buffer (2% BSA and 0.05% Triton-X in PBS) in a humidified chamber at RT for 1 h. The blocking buffer was drained from the slides, appropriate diluted primary antibodies (Ki-67, p-Akt) were added, and the slides were incubated overnight at 4°C. The slides were then washed three times with PBS and incubated with secondary antibodies for 1 h at RT. The slides were washed again three times with PBS and the sections were covered with a coverslip. Immunohistochemical staining was performed using horseradish peroxidase (HRP).

TUNEL analysis

Analysis of the apoptotic marker TUNEL was performed using the TUNEL assay kit from Servicebio (Wuhan, China). The sections were incubated twice with xylene for 15–20 min each. The cells were dehydrated with two times of pure ethanol for 10 min each, followed by dehydration with 95%, 90%, 80%, and 70% gradient ethanol for 5 min each. Clear fluid was removed, and markers were made on the target tissue with a hydroresistive pen. Proteinase K working solution was added to cover the target and incubated at 37°C for 25 min. They were then washed 3 times for 5 min each with PBS (pH 7.4) in a Rocker device. Excess fluid was removed and permeable working solution was added to cover the target tissue, followed by incubation for 20 min at room temperature. The plates were washed three times with PBS (pH 7.4) in a Rocker device. According to the number of sections and tissue size, appropriate amounts of TDT enzyme, dUTP, and buffer were mixed in the TUNEL kit at a ratio of 1:5:50. This reaction solution was prepared as needed before use. This mixture was added to the target tissue placed in a flat wet box and incubated for 2 h at 37°C. DAPI counterstained nuclei were washed three times with PBS (pH 7.4) for 5 min each in a Rocker apparatus. They were then washed with PBS (pH 7.4) three times for 5 min each in a Rocker device. Discard the liquid slightly and cover with anti-fade mounting medium. Microscopy and image acquisition were performed using a fluorescence microscope (Olympus Optical Co., Tokyo, Japan): DAPI emitted blue light, UV excitation wavelength 330–380 nm, emission wavelength 420 nm; TUNEL emitted green fluorescence with an excitation wavelength of 465–495 nm and an emission wavelength of 515–555 nm.

Statistical analysis

All data were presented as mean ± standard deviation (SD) of 3 independent experiments. All statistical analyses were performed using GraphPad Prism 5.2 software (GraphPad Software, Inc.). The difference between two groups was analyzed by Student’s t-test. The difference among multiple groups was analyzed by one-way analysis of variance. P < 0.05 was used to suggest statistical significance.

Results

MLT significantly inhibited the proliferation of RCC in vitro and in vivo

To detect the effect of MLT on cell growth of RCC cells, 786-O, 769-P, SW839 cells were treated with different concentrations (2.0 and 4.0 mmol/L) of MLT for 24 h and MTT assay was performed to detect cell proliferation. As shown in Figure 1(A–C), the proliferation of all these RCC cells was inhibited by MLT treatment in a dose-dependent manner. The IC50 of MLT for 786-O, 769-P, and SW839 cells was 2.4, 2.7, and 2.0 mM, respectively (Figure 1(A–C)). It was also obvious that the number of RCC cells was progressively reduced with the increase of MLT concentration as shown in the microscopic images (Figure 1(D)) and quantification (Figure S1A). Colony formation assay was performed to assess the anti-proliferative effect of MLT, and we found that proliferative ability of RCC cells in the MTL groups showed a greater decrease than that in the control groups (Figure 1(E)). In order to verify whether MLT has effect on the proliferation of normal Renal Proximal Tubule Epithelial Cells, we performed MTT assay, microscopic observation, and colony formation assay, and found that MLT at the maximum concentration of 4mM had no toxic effect on HK-2 cells (Figure S1B, 1C, 1D). To investigate the effect of MLT on RCC growth in vivo, 786-O cells were injected into BALB/c nude mice to form subcutaneous xenograft tumors. After treatment with MLT for 12 days, there was no significant difference in body weight between the MLT treatment group and the control group (Figure 1(F)). However, the tumor volume was clearly decreased in the MLT-treated nude mice (Figure 1(G)). After sacrificing, isolated tumors were photographed and weighed, and we found that net tumor weight was significantly decreased in the MLT-treated group (Figure 1(H,I)). These results demonstrated that MLT inhibited the growth of RCC cell xenografts in nude mice without affecting their body weight. Similar to the cell experiments, we also investigated the ATP production in the tumor tissues of nude mice after MLT treatment and found that more ATP was generated compared with the control group (Figure 1(J)). Taken together, these results indicated that MLT inhibits RCC cell proliferation in vitro and in vivo.

Figure 1.

Figure 1.

Open in a new tab

MLT Significantly inhibited the proliferation of RCC In vivo and in vitro. (A, B, C) Relative cell viability of 786-O, 769-P and SW839 cells treated with MLT at different concentrations for 24 h was measured by MTT assays. (D) 786-O, 769-P and SW839 cells treated with MLT at different concentrations for 24 h. Cells were stained with trypan blue, and the number of the cells is shown for different group. (E) Colony formation test of RCC cells after treated with MLT. (F) The nude mouse body weight was measured every 2 days with/without MLT treatment. (G) The nude mouse tumor volume was measured every 2 days with/without MLT treatment. (H) After sacrificing, tumors were isolated and photographed after treatment with/without MLT for 12 days. (I) After sacrificing, tumors were isolated and weighted after treatment with/without MLT for 12 days. (J) The level of ATP in mouse tumors was measured (n = 3, mean ± SD).

MLT treatment increased ROS production and inhibits antioxidases activities in RCC

The mechanistic basis of cell damage induced by MLT is closely associated with the generation of intracellular ROS. It has been reported that MLT affects the deacetylase SIRT3 in the mitochondria of myocardial cells, thereby affecting its substrate Ack122-MnSOD [28]. Therefore, we verified the biological function of SIRT3 in RCC cells by extracting mitochondria for western blotting analysis and used the 3-TYP (inhibitor of SIRT3) to advance MTT analysis. Interestingly, the expression level of Ack122-MnSOD was increased in RCC cells (Figure S2A, 2B, 2C), which was mutually refuted with the increase of ROS, and 3-TYP did not reduce cell death (Figure S2D, 2E, 2F). These results indicate that the inhibition of RCC cell growth by MLT is not through the enhancement of SIRT3 function. Therefore, we investigated the relationship between the increase of ROS and other antioxidant enzymes in MLT-treated RCC cells. Consistent with previous studies, we found that MLT significantly increased the fluorescence intensity of the intracellular ROS probe compared to the other treatments under a fluorescence microscope (Figure 2(B)). Moreover, the results of flow cytometry showed that the amount of ROS in the MLT group increased significantly (Figure 2(A,C,D,E)). In addition, activities of SOD, GSH, GSH-Px, and CAT were measured in order to detect the antioxidant capacity of MLT in RCC. As shown in Figure 2(F–I), the activities of SOD, GSH, and CAT significantly decreased in the group treated with MLT, whereas the activities of GSH-Px increased in the MLT-treated cells. Collectively, MLT treatment increased ROS production and inhibits antioxidase activities in RCC cells.

Figure 2.

Figure 2.

Open in a new tab

MLT treatment increased ROS production and inhibited antioxidase activities in RCC cells. (A) ROS production in RCC cells were detected by fluorescence staining. Scale bar = 50 μm. (B, C, D, E) Flow cytometry analysis of the ROS amount and quantitative analysis of intracellular ROS detection. (n = 3, mean ± SD). (F) SOD activity in 786-O, 769-P and SW839 cells after treatment with MLT 24 h; (n = 3, mean ± SD). (G) GSH activity in 786-O, 769-P and SW839 cells after treatment with MLT 24 h; (n = 3, mean ± SD). (H) GSH-PX activity in 786-O, 769-P and SW839 cells after treatment with MLT 24 h; (n = 3, mean ± SD). (I) CAT activity in 786-O, 769-P and SW839 cells after treatment with MLT 24 h; (n = 3, mean ± SD). *p < 0.05; **p < 0.01, and ***p < 0.001 vs control group.

MLT significantly promotes cell apoptosis of RCC cells, which is attenuated by NAC

To investigate whether MLT induces apoptosis of RCC cells, 786-O,769-P, and SW839 cells were exposed to different concentrations of MLT (2 and 4 mM), and changes in the expression of associated proteins (PARP, cleaved-PARP, Caspase-3, cleaved-Caspase-3, Bax, Bcl-2) were detected via western blotting analysis. As shown in Figure 3(A), MLT treatment resulted in the reduction of expression of anti-apoptotic protein Bcl-2, whereas increased pro-apoptotic protein Bax expression. Moreover, the expression levels of cleaved PARP and cleaved caspase-3 were increased by MLT treatment, suggesting that MLT treatment activated the downstream signaling molecules. Consistent with these results, MLT increased the percentage of apoptotic cells in 786-O,769-P, and SW839 cells, as evaluated by Annexin V/PI staining and flow cytometry assay (Figure 3(B); Figure S1E, S1F, S1G). Moreover, given the importance of ROS in MLT treatment, the scavenger NAC was used to evaluate the role of ROS in the apoptotic and related pathways. We found that the expression levels of apoptosis associated proteins were reversed (Figure 3(C)), and the number of apoptotic cells obtained by flow cytometry was significantly reduced compared with the MLT-treatment groups (Figure 3(D), Figure S1H). Cell apoptosis (TUNEL) expression in tumor tissues were analyzed by immunofluorescent staining assay (Figure 3(E)). It was shown that MLT treatment increased the TUNEL expression in vivo, confirming that MLT treatment induced cell apoptosis and suppressed cell proliferation of RCC cells in vivo.

Figure 3.

Figure 3.

Open in a new tab

MLT Significantly promotes apoptosis of RCC and and is attenuated by NAC. (A) The RCC cells were treated with different doses of MLT for 24, and then protein expression was detected by western blotting analysis. (B) 786-O, 769-P and SW839 cells were pretreated with MLT (0, 2, and 4 mM) for 24 h, and cell apoptosis was detected by flow cytometry analysis. (C) Western blot analysis of the expression levels of apoptosis related proteins after 786-O, 769-P and SW839 cells treated with MLT (4 mM) and ROS inhibitor NAC (5 mM). (D) The apoptotic cell number changes in 786-O, 769-P and SW839 cells after treatment with MLT (4 mM) and ROS inhibitor NAC (5 mM) as detected by flow cytometry assay. (E) Representative images showing immunofluorescence of staining for TUNEL and in RCC cell xenografts (scale bar  = 20 μm).

MLT treatment up-regulated key TCA cycle metabolites while reduced aerobic glycolysis products in RCC cells

The role of MLT in the regulation of cancer cell metabolism remains largely unexplored. Therefore, we wondered whether the increase of ROS in renal cancer cells by MLT treatment was related to the tricarboxylic acid cycle in mitochondria. To further dissect the effects of MLT in cancer metabolism, we carried out metabolomic analyses using UPLC-MS/MS and found obvious differences between the control group and the MLT-treated group (Figure 4(A)). We found that after the treatment by MLT for 6 h, key TCA cycle metabolites, including Acetyl-CoA, citrate, isocitrate and succinate were upregulated in RCC cells (Figure 4(B–D)), while the levels of pyruvate (Figure 4(E)) and lactate were reduced (Figure 4(F)). A larger influx of pyruvate into the mitochondria would lead to enhanced oxidative phosphorylation and reduced lactate production, which may lead to mitochondrial ROS production. These results indicate that MLT treatment inhibited aerobic glycolysis but enhanced the TCA cycle in RCC cells.

Figure 4.

Figure 4.

Open in a new tab

MLT treatment up-regulated key TCA cycle metabolites while reduced aerobic glycolysis products in RCC cells. (A) Heatmap of the metabolomic analysis in 786-O cells between MLT-treated groups vs. control group. (B, C, D, E, F, G) Metabolomic analysis of intracellular levels of Acetyl-CoA, citrate, isocitrate, succinate, pyruvate and lactate respectively, as detected using UPLC-MS/MS. (n = 3, mean ± SD). * p < 0.05; ** p < 0.01 and *** p < 0.001 vs control group.

MLT treatment enhanced mitochondrial function in RCC cells

It has been reported that MLT may influence mitochondrial energy metabolism including OXPHOS when it functions as an antioxidant [29]. To further determine whether the metabolic reprogramming in RCC cells after MLT treatment was related to their mitochondria function change, functional mitochondrial analyses were carried out using the Seahorse XF96 extracellular flux analyzer in 786-O, 769-P, and SW839 cells (Figure 5(A–C)). Consistent with previous findings, elevated OCR corresponding to increased basal respiration with the increasing of MLT concentration was observed in RCC cells (Figure 5(E–F)). In addition, the ATP turnover (ATP production), maximal respiration and the proton leak of mitochondrial in RCC were increased after treated with MLT (Figure S3A, S3B, S3C), indicating that MLT reverses the impaired basic respiratory function and partially restores the maximal respiratory function of the mitochondria in RCC cells. Moreover, flow cytometry analysis by JC-1 staining revealed the enhanced mitochondrial membrane potential in MLT-treated cells (Figure 5(G,H)), suggesting that the membrane potential and the mitochondrial capacity of RCC cells were significantly increased after MLT application. Consistently, we found that MLT-treated groups significantly increased the RED fluorescence intensity and decreased the GREEN fluorescence intensity of the intracellular JC-1 probe compared to the control groups under a fluorescence microscope (Figure 5(I)). This was also verified by the higher level of ATP in RCC cells after treatment with MLT (Figure 5(J–L)). Taken together, these findings indicate that MLT treatment enhanced mitochondrial function and inhibited aerobic glycolysis (the Warburg effect) in cancer cells causing them to revert to mitochondrial OXPHOS and increase the ROS production, which may result in the inhibition of cancer cell proliferation and promotion of cell apoptosis.

Figure 5.

Figure 5.

Open in a new tab

MLT treatment enhanced mitochondrial function in RCC cells. (A, B, C) OCR level of 786-O, 769-P and SW839 cells pretreated with different dose of MLT for 24h as measured by seahorse analyzer Oligomycin A, Fccp, and Rotenone/Antimycin A (n = 5, mean ± SD). (D, E, F) The basal respiration in 786-O, 769-P, and SW839 cells respectively. (n = 5, mean ± SD). (G, H) The mitochondrial membrane potential changes in 786-O, 769-P, and SW839 cells after treatment with MLT for 24 h, as detected by flow cytometry analysis, and the quantification of JC-1 green is shown in bar graph (H), in which the lower JC-1 green indicates the higher membrane potential. (n = 3, mean ± SD). (I) Fluorescence diagrams of mitochondrial membrane potential with RED and GREEN changes in 786-O, 769-P and SW839 cells after treatment with MLT for 24h, in which the lower JC-1 Green/Red ration indicates the higher membrane potential. Scale bar = 50 μm. (J, K, L) Level of ATP in 786-O, 769-P and SW839 cells after treatment with MLT at different concentrations, respectively. (n = 3, mean ± SD). * p < 0.05; ** p < 0.01 and *** p < 0.001 vs control group.

MLT treatment suppressed Akt/mTOR/S6K signaling pathway and reduced HIF-1ɑ/VEGF expression via inhibiting ROS production

It has long been demonstrated that ROS-mediated cell apoptosis is related to Akt/mTOR/S6K signaling pathways [20]. To verify whether cell apoptosis in RCC cells was related to the ROS/Akt/mTOR/S6K signaling pathways, we performed western blotting analysis and found that the expression levels of p-Akt and p-mTOR, p-p70 S6 Kinase (Thr389/Ser371) in the MLT treatment groups (4 mM) were significantly decreased compared with the control groups (Figure 6(A)), indicating that Akt/mTOR/S6K signaling pathway was inhibited by MLT treatment. In particular, the protein expression of p-p70 S6 Kinase (Thr389) of 786-O and 769-P was not inhibited, while SW839 was significantly inhibited. The expression levels of HIF-1ɑ and VEGF in the MLT treatment groups (4 mM) were significantly decreased compared with the control groups (Figure 6(B)). Moreover, given the importance of ROS in MLT treatment, the scavenger NAC was used to evaluate the role of ROS in the related pathways. We found that the Akt/mTOR/S6K signaling pathway was reactivated by the addition of NAC compared with the MLT-treatment groups (Figure 6(C)). On the other hand, cell proliferation (Ki-67) and p-Akt expression in tumor tissues were analyzed by H&E, IHC staining assay (Figure 6(D)). It was shown that MLT treatment inhibited expression level of Ki-67 and p-Akt, confirming that MLT treatment inhibited the activity of Akt/mTOR/S6K signaling pathway in vivo. In summary, these results indicate that MLT treatment suppressed Akt/mTOR/S6K signaling pathway and reduced HIF-1ɑ/VEGF expression via enhancing ROS production, which may lead to induction of cell apoptosis and decrease of angiogenesis of RCC. Schematic diagram of how melatonin causes apoptosis in RCC cells was shown in Figure 6(E).

Figure 6.

Figure 6.

Open in a new tab

MLT induced cell apoptosis via regulating the ROS-mediated suppression of Akt/mTOR/S6K signaling pathway. (A) Western blot analysis of Akt, p-Akt and mTOR, p-mTOR, p-p70 S6 Kinase (Thr389/Ser371) and β-actin expression, after 786-O, 769-P and SW839 cells were treated with different concentrations MLT for 24 h. (B) Western blot analysis of the expression levels of HIF-1ɑ and VEGF after 786-O, 769-P and SW839 cells treated with MLT (4 mM) and ROS inhibitor NAC (5 mM). (C) Western blot analysis of the expression Akt, p-Akt and mTOR, p-mTOR, p-p70 S6 Kinase (Thr389/Ser371), and β-actin after RCC cells treated with MLT (4 mM) and ROS inhibitor NAC (5 mM). (D) Representative images showing immunocytochemical of staining for HE, Ki-67 and p-Akt in RCC cell xenografts (scale bar  = 20 μm). (E) Schematic diagram of how melatonin causes apoptosis in RCC cells.

Sunitinib increased the Warburg effect in RCC cells

To determine whether sunitinib treatment increase glycolysis activity of RCC cells, we first examined the IC50 of sunitinib in RCC (Figure 7(A)). Moreover, we found that after the treatment by sunitinib for 24 h, pyruvate is upregulated in RCC cells (Figure 7(B)). On the other hand, we observed reduced OCR and elevated the extracellular acidification rate (ECAR) corresponding to decreased basal respiration (Figure 7(C,D)) in the sunitinib treatment groups (10 μM). In addition, the ATP turnover (ATP production), maximal respiration and the proton leak of mitochondrial in RCC were decreasing after treated with sunitinib (Figure S3D, S3E, S3F), indicating that sunitinib breaks the maximal respiratory function of the mitochondria in RCC cells and increases the Warburg effect in RCC.

Figure 7.

Figure 7.

Open in a new tab

Sunitinib enhances the Warburg effect in RCC. (A) Relative cell viability of 786-O, 769-P and SW839 cells treated with sunitinib at different concentrations for 24 h was measured by MTT assays. (B) Pyruvate activity in 786-O, 769-P and SW839 cells after treatment with sunitinib for 24 h; (n = 3, mean ± SD). (C, D) OCR and ECAR level of 786-O, 769-P and SW839 cells pretreated with different dose of sunitinib for 24h as measured by seahorse analyzer. (E) The basal respiration in 786-O, 769-P, and SW839 cells respectively. (n = 5, mean ± SD). ** p < 0.01 and *** p < 0.001 vs control group.

MLT synergistically inhibited cell growth with sunitinib and reversed the Warburg effect induced by sunitinib in RCC cells

We next investigated the combined effects of MLT and sunitinib on RCC cell viability. With the addition of 10 μM of sunitinib, MLT treatment decreased cell viability in a dose-dependent manner, achieving the maximal effect at a concentration of 2 mM (Figure 8(A)). Interestingly, the combination of MLT (2mM) and sunitinib (10 μM) significantly decreased the pyruvate activity of RCC cells to the lowest level compared to the other treatments (Figure 8(B)). Moreover, the effect of combined MLT and sunitinib on glycolytic activity in RCC cells showed an increased OCR and a decreased ECAR after 24 h of treatment with high doses of MLT corresponding to increased basal respiration (Figure 8(C,D)) in the MLT treatment groups. In addition, the ATP turnover (ATP production), maximal respiration and of mitochondria in RCC cells were increasing after treated with MLT (2 mM) (Figure S3G, S3H). The results regarding respiration were in line with the observation that melatonin enhances the effects of sunitinib, in terms of reversing the Warburg effect in RCC.

Figure 8.

Figure 8.

Open in a new tab

MLT enhances effects of sunitinib, reversing the Warburg effect in RCC. (A) Relative cell viability of 786-O, 769-P and SW839 cells treated with sunitinib and MLT at different concentrations for 24 h was measured by MTT assays. (B) Pyruvate activity in 786-O, 769-P and SW839 cells after treatment with MLT and sunitinib for 24 h; (n = 3, mean ± SD). (C, D) OCR and ECAR level of 786-O, 769-P and SW839 cells pretreated with different dose of sunitinib and MLT for 24h as measured by seahorse analyzer. (E) The basal respiration in 786-O, 769-P, and SW839 cells respectively. (n = 5, mean ± SD). ** p < 0.01 and *** p < 0.001 vs control group.

Discussions

In the last decade, a large number of basic and clinical studies have demonstrated that MLT treatment is effective for a multitude of diseases, including cancer, metabolic diseases, neurodegeneration, metabolic diseases, and diabetes [14, 18, 19, 30, 31]. However, the effect of MLT on RCC remains unknown. Herein, we found that MLT significantly inhibited proliferation and induced cell apoptosis in RCC cells in vitro and in vivo. Mechanistically, we found that MLT increased the level of TCA cycle metabolites and oxidative phosphorylation in mitochondria, as well as inhibited the activity of antioxidant enzymes, leading to the reversal of the Warburg effect and the increase of ROS. Furthermore, our results demonstrated that the anti-proliferative effects of MLT in RCC are due to the suppression of Akt/mTOR/S6K signaling pathway mediated by ROS, resulting in enhanced cell apoptosis and inhibited cell proliferation (Figure 6). These findings indicate that MLT might be a promising drug to inhibit tumor growth by reprogramming mitochondrial function and altering the activity of antioxidant enzymes.

In recent years, it has been elucidated that mitochondria plays a major role in the metabolic reprogramming of tumor cells to rapidly adapt to stress conditions such as hypoxia and nutrient limitation, which is considered a hallmark of cancer [32, 33]. The Warburg effect suggests that cancer cells, even in the presence of sufficient oxygen, produce ATP and large amounts of lactic acid by glycolysis [34]. The generation of lactic acid creates an acidic environment that provides a more favorable condition for cancer cell proliferation, invasion and metastasis [35]. Therefore, inhibition of glycolysis by molecules is considered as an effective strategy to reduce metastasis via reversing the Warburg effect and re-instituting mitochondrial OXPHOS [36–38]. As we know, MLT is a well-known endogenously-produced molecule involved in antioxidation [39]. Our results indicate that MLT treatment increases TCA intermediates such as Acetyl-CoA, citrate, isocitrate and succinate, but decreased pyruvate and lactate levels (Figure 3). Pyruvate enters mitochondria from cytosol and it is the key substance linking glycolysis and mitochondrial oxidative phosphorylation. The decrease in lactate and pyruvate after MLT treatment suggests that melatonin can inhibit or even reverse the Warburg effect and metabolic reprogramming in cancer cells. Our findings also indicated that in cancer cells after melatonin treatment, TCA and OXPHOS are significantly increased, while glycolysis was decreased, resulting in more ATP and ROS production. Moreover, we determined the impact of MLT on the behavior of mitochondria in cellular metabolism, and the enhancement of ATP, the increase of ATP production-coupled OCR, basal respiration, and membrane potential, indicated that mitochondria function was improved by MLT (Figure 4). Taken together, our findings indicate that MLT treatment triggered the metabolic reprogramming via inhibition of glycolysis, increase of TCA and OXPHOS, and improvement of mitochondria function, which may result in more ATP and ROS production in RCC cells.

The cellular redox state is determined by the ratio of antioxidants to oxidants [40]. Antioxidants include the enzymes SOD, glutathione peroxidase (GPx), and CAT, and nonenzymes such as GSH and vitamins A, C, and E. Oxidants include ROS such as hydrogen peroxide (H2O2), superoxide anion radical (O2•-), and hydroxyl radical (•OH) [41–43]. In this study, we found that the activity of antioxidant enzymes SOD, CAT, and GSH decreased by MLT treatment (Figure 2), which may lead to the reduction of oxidant consumption. On the other hand, MLT treatment enhanced TCA cycle and OXPHOS and improved mitochondria function in RCC cells, which may lead to more ROS production (Figures 3 and 4). Thus, in RCC cells less ROS consumption and more ROS production induced by MLT may work together, resulting in the increase of intracellular ROS concentration (Figure 2). Since MLT-inducing apoptosis in cancer cells is associated with ROS production [44–46], this increase could lead to the inhibition of cell growth of RCC.

In the research of cancer, the exploration of molecular mechanisms is of great help for the treatment of cancer and may form new therapeutic targets. In this regard, among the abnormal molecular mechanism of MLT regulation, several studies have shown that mTOR signaling pathway is crucial with ROS [20, 47]. Unexpected Akt activation leads to activation of mTOR, which contributes to cell growth, proliferation and metabolism, and promotes tumourigenesis [48, 49]. Activation of mTOR results in increased protein synthesis and cell survival by direct phosphorylation of its effectors, such as the ribosomal S6K [50]. Until now, however, the effects of MLT on Akt/mTOR/S6K signaling pathway and redox homeostasis in RCC remain to be explored. ROS can regulate signaling pathways of Akt/mTOR/S6K to different degrees. For instance, low ROS levels promote mTOR activity, whereas high ROS levels inhibit mTOR activity [51]. A previous study has shown that combination of MLT and rapamycin promoted cell apoptosis and autophagy in head and neck cancer by inhibiting Akt/mTOR signaling pathway [20]. However, it is unclear whether increased ROS mediated apoptosis through Akt/mTOR/S6K signaling pathway in MLT-treated RCC. Therefore, we analyzed RCC treated with MLT by western blotting analysis and found that p-Akt, p-mTOR and p-p70 S6 Kinase (Ser371) protein expression was inhibited. To verify that this process is mediated by ROS, NAC (inhibitors of ROS) was used and we found that p-Akt, p-mTOR and p-p70 S6 Kinase (Ser371) levels were restored. As a consequence, ROS could play a key role in RCC through Akt/mTOR/S6K inactivation. In a nutshell, the increase in ROS was attributed to enhanced mitochondrial function and decreased antioxidant enzyme activity after MLT treatment, while ROS can also be used as inducers of tumor cell apoptotic through the Akt/mTOR/S6K signaling pathway. Overall, our study provides new insights into the mechanisms underlying melatonin’s anti-tumor activity in RCC.

Our results indicated that the combination of MLT and sunitinib affected mitochondrial homoeostasis in the RCC. Sunitinib significantly increased pyruvate activity, decreased OCR and increased ECAR in RCC. This is consistent with increased glycolysis activity in the metabolic microenvironment in sunitinib resistance studies [52]. Therefore, MLT can reverse the changes in this microenvironment and increase the efficacy of sunitinib.

A meta-analysis study showed that MLT treatment significantly reduced solid tumor size and improved 1-year mortality [53]. According to our findings, MLT also inhibited the growth of RCC in vivo. The growth of 786-O cell-derived tumor xenografts in mice was significantly inhibited by MLT. Consistent with the in vitro results, the tumor tissues of mice treated with MLT produced more ATP than those of controls; moreover, the expression in Ki-67 and p-Akt were decreased, while the TUNEL was increased, confirming that MLT inhibited RCC cell proliferation and promoted cell apoptosis. Considering that mTOR is a clinically accepted treatment target in RCC and low toxicity of MLT because it is an endogenously-produced molecule in human body, MLT might be a promising drug for RCC treatment. However, large-scale clinical trials are needed to confirm the efficacy of MLT treatment in RCC patients in the future.

In conclusion, our results indicate that MLT treatment reverses the Warburg effect and promotes intracellular ROS production, which leads to the suppression of Akt/mTOR/S6K signaling pathway, induction of cell apoptosis, and synergistically inhibition of cell growth with sunitinib in RCC cells. Overall, this study provides new insights into the mechanisms underlying anti-tumor effect of MLT in RCC cells, and suggests that MLT might be a promising therapeutic for RCC.

Supplementary Material

Supplemental Material
Click here for additional data file. (1.1MB, tif)
Supplemental Material
Click here for additional data file. (1.5MB, tif)
Supplemental Material
Click here for additional data file. (3.4MB, tif)

Acknowledgements

KX, YJ, and PG designed and performed the experiments, analyzed the data, and wrote the paper; JB, DZ, YC, JM and ZZ performed the experiments and analyzed the data; XW and PG coordinated and supervised the experiments.

Funding Statement

This study was supported by the National Natural Science Foundation of China (NSFC No. 82172797 to P.G.).

Disclosure statement

No potential conflict of interest was reported by the author(s).

Data availability

The data and materials during the current study are available from the corresponding author on reasonable request.

Ethical approval

All protocols used for animal manipulation were approved by the Institutional Animal Care Committee.

References

  • 1.Siegel RL, Miller KD, Fuchs HE, et al. . Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. doi: 10.3322/caac.21708 [DOI] [PubMed] [Google Scholar]
  • 2. Marston Linehan. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499(7456):43–49. doi: 10.1038/nature12222 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Linehan WM, Schmidt LS, Crooks DR, et al. . The metabolic basis of kidney cancer. Cancer Discov. 2019;9(8):1006–1021. doi: 10.1158/2159-8290.CD-18-1354 [DOI] [PubMed] [Google Scholar]
  • 4.DiNatale RG, Sanchez A, Hakimi AA, et al. . Metabolomics informs common patterns of molecular dysfunction across histologies of renal cell carcinoma. Urol Oncol. 2020;38(10):755–762. doi: 10.1016/j.urolonc.2019.04.028 [DOI] [PubMed] [Google Scholar]
  • 5.Jin T, Wang C, Tian Y, et al. . Somatic gene mutation signatures predict cancer type and prognosis in multiple cancers with pan-cancer 1000 gene panel. Cancer Lett. 2020;470:181–190. doi: 10.1016/j.canlet.2019.11.022 [DOI] [PubMed] [Google Scholar]
  • 6.Yoshida GJ. Metabolic reprogramming: the emerging concept and associated therapeutic strategies. J Exp Clin Cancer Res. 2015;34:111. doi: 10.1186/s13046-015-0221-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Zong WX, Rabinowitz JD, White E.. Mitochondria and cancer. Mol Cell. 2016;61(5):667–676. doi: 10.1016/j.molcel.2016.02.011 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Spinelli JB, Haigis MC.. The multifaceted contributions of mitochondria to cellular metabolism. Nat Cell Biol. 2018;20(7):745–754. doi: 10.1038/s41556-018-0124-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Keckesova Z, Donaher JL, Cock D, et al. . LACTB is a tumour suppressor that modulates lipid metabolism and cell state. Nature. 2017;543(7647):681–686. doi: 10.1038/nature21408 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Yang Y, Karakhanova S, Hartwig W, et al. . Mitochondria and mitochondrial ROS in cancer: novel targets for anticancer therapy. J Cell Physiol. 2016;231(12):2570–2581. doi: 10.1002/jcp.25349 [DOI] [PubMed] [Google Scholar]
  • 11.Sabharwal SS, Schumacker PT.. Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles’ heel? Nat Rev Cancer. 2014;14(11):709–721. doi: 10.1038/nrc3803 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Poprac P, Jomova K, Simunkova M, et al. . Targeting free radicals in oxidative stress-related human diseases. Trends Pharmacol Sci. 2017;38(7):592–607. doi: 10.1016/j.tips.2017.04.005 [DOI] [PubMed] [Google Scholar]
  • 13.Luchetti F, Canonico B, Betti M, et al. . Melatonin signaling and cell protection function. Faseb J. 2010;24(10):3603–3624. doi: 10.1096/fj.10-154450 [DOI] [PubMed] [Google Scholar]
  • 14.Venegas C, García JA, Escames G, et al. . Extrapineal melatonin: analysis of its subcellular distribution and daily fluctuations. J Pineal Res. 2012;52(2):217–227. doi: 10.1111/j.1600-079X.2011.00931.x [DOI] [PubMed] [Google Scholar]
  • 15.Audet-Walsh É, Papadopoli DJ, Gravel SP, et al. . The PGC-1α/ERRα axis represses One-carbon metabolism and promotes sensitivity to anti-folate therapy in breast cancer. Cell Rep. 2016;14(4):920–931. doi: 10.1016/j.celrep.2015.12.086 [DOI] [PubMed] [Google Scholar]
  • 16.Chen X, Hao B, Li D, et al. . Melatonin inhibits lung cancer development by reversing the Warburg effect via stimulating the SIRT3/PDH axis. J Pineal Res. 2021;71(2):e12755. doi: 10.1111/jpi.12755 [DOI] [PubMed] [Google Scholar]
  • 17.Reiter RJ, Sharma R, Ma Q, et al. . Melatonin inhibits Warburg-dependent cancer by redirecting glucose oxidation to the mitochondria: a mechanistic hypothesis. Cell Mol Life Sci. 2020;77(13):2527–2542. doi: 10.1007/s00018-019-03438-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Talib WH. Melatonin and cancer hallmarks. Molecules. 2018;23(3). doi: 10.3390/molecules23030518 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Chao CC, Chen PC, Chiou PC, et al. . Melatonin suppresses lung cancer metastasis by inhibition of epithelial-mesenchymal transition through targeting to twist. Clin Sci (Lond). 2019;133(5):709–722. doi: 10.1042/CS20180945 [DOI] [PubMed] [Google Scholar]
  • 20.Shen YQ, Guerra-Librero A, Fernandez-Gil BI, et al. . Combination of melatonin and rapamycin for head and neck cancer therapy: suppression of AKT/mTOR pathway activation, and activation of mitophagy and apoptosis via mitochondrial function regulation. J Pineal Res. 2018;64(3):e12461. [DOI] [PubMed] [Google Scholar]
  • 21.Ma Z, Yang Y, Fan C, et al. . Fluorouracil-based neoadjuvant chemoradiotherapy with or without oxaliplatin for treatment of locally advanced rectal cancer: An updated systematic review and meta-analysis. Oncotarget. 2016;7(29):45513–45524. doi: 10.18632/oncotarget.9995 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Chakraborty S, Balan M, Sabarwal A, et al. . Metabolic reprogramming in renal cancer: events of a metabolic disease. Biochim Biophys Acta Rev Cancer. 2021;1876(1):188559. doi: 10.1016/j.bbcan.2021.188559 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Motzer RJ, Penkov K, Haanen J, et al. . Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1103–1115. doi: 10.1056/NEJMoa1816047 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Albiges L, Tannir NM, Burotto M, et al. . Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open. 2020;5(6):e001079. doi: 10.1136/esmoopen-2020-001079 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Randrup Hansen C, Grimm D, Bauer J, et al. . Effects and side effects of using sorafenib and sunitinib in the treatment of metastatic renal cell carcinoma. Int J Mol Sci. 2017;18(2). doi: 10.3390/ijms18020461 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Zhang MX, Wang JL, Mo CQ, et al. . CircME1 promotes aerobic glycolysis and sunitinib resistance of clear cell renal cell carcinoma through cis-regulation of ME1. Oncogene. 2022;41(33):3979–3990. doi: 10.1038/s41388-022-02386-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Xiao C, Zhang W, Hua M, et al. . RNF7 inhibits apoptosis and sunitinib sensitivity and promotes glycolysis in renal cell carcinoma via the SOCS1/JAK/STAT3 feedback loop. Cell Mol Biol Lett. 2022;27(1):36. doi: 10.1186/s11658-022-00337-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Feng J, Chen X, Liu R, et al. . Melatonin protects against myocardial ischemia-reperfusion injury by elevating Sirtuin3 expression and manganese superoxide dismutase activity. Free Radic Res. 2018;52(8):840–849. doi: 10.1080/10715762.2018.1461215 [DOI] [PubMed] [Google Scholar]
  • 29.Bilska B, Schedel F, Piotrowska A, et al. . Mitochondrial function is controlled by melatonin and its metabolites in vitro in human melanoma cells. J Pineal Res. 2021;70(3):e12728. doi: 10.1111/jpi.12728 [DOI] [PubMed] [Google Scholar]
  • 30.García JJ, López-Pingarrón L, Almeida-Souza P, et al. . Protective effects of melatonin in reducing oxidative stress and in preserving the fluidity of biological membranes: a review. J Pineal Res. 2014;56(3):225–237. doi: 10.1111/jpi.12128 [DOI] [PubMed] [Google Scholar]
  • 31.Halpern B, Mancini MC, Bueno C, et al. . Melatonin increases brown adipose tissue volume and activity in patients with melatonin deficiency: a proof-of-concept study. Diabetes. 2019;68(5):947–952. doi: 10.2337/db18-0956 [DOI] [PubMed] [Google Scholar]
  • 32.Herst PM, Grasso C, Berridge MV.. Metabolic reprogramming of mitochondrial respiration in metastatic cancer. Cancer Metastasis Rev. 2018;37(4):643–653. doi: 10.1007/s10555-018-9769-2 [DOI] [PubMed] [Google Scholar]
  • 33.Meng F, Wu L, Dong L, et al. . EGFL9 promotes breast cancer metastasis by inducing cMET activation and metabolic reprogramming. Nat Commun. 2019;10(1):5033. doi: 10.1038/s41467-019-13034-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Gerresheim GK, Roeb E, Michel AM, et al. . Hepatitis C virus downregulates core subunits of oxidative phosphorylation, reminiscent of the Warburg effect in cancer cells. Cells. 2019;8(11). doi: 10.3390/cells8111410 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Reiter RJ, Sharma R, Ma Q.. Switching diseased cells from cytosolic aerobic glycolysis to mitochondrial oxidative phosphorylation: a metabolic rhythm regulated by melatonin? J Pineal Res. 2021;70(1):e12677. doi: 10.1111/jpi.12677 [DOI] [PubMed] [Google Scholar]
  • 36.Akram M. Mini-review on glycolysis and cancer. J Cancer Educ. 2013;28(3):454–457. doi: 10.1007/s13187-013-0486-9 [DOI] [PubMed] [Google Scholar]
  • 37.Zhao X, Bai Z, Wu P, et al. . S100p enhances the chemosensitivity of human gastric cancer cell lines. Cancer Biomark. 2013;13(1):1–10. doi: 10.3233/CBM-130330 [DOI] [PubMed] [Google Scholar]
  • 38.Zhao X, Liu J, Peng M, et al. . BMP4 is involved in the chemoresistance of myeloid leukemia cells through regulating autophagy-apoptosis balance. Cancer Invest. 2013;31(8):555–562. doi: 10.3109/07357907.2013.834925 [DOI] [PubMed] [Google Scholar]
  • 39.Reiter RJ, Mayo JC, Tan DX, et al. . Melatonin as an antioxidant: under promises but over delivers. J Pineal Res. 2016;61(3):253–278. doi: 10.1111/jpi.12360 [DOI] [PubMed] [Google Scholar]
  • 40.Cruz-Gregorio A, Aranda-Rivera AK, Pedraza-Chaverri J, et al. . Redox-sensitive signaling pathways in renal cell carcinoma. Biofactors. 2022;48(2):342–358. doi: 10.1002/biof.1784 [DOI] [PubMed] [Google Scholar]
  • 41.Cadenas E. Basic mechanisms of antioxidant activity. Biofactors. 1997;6(4):391–397. doi: 10.1002/biof.5520060404 [DOI] [PubMed] [Google Scholar]
  • 42.Kryston TB, Georgiev AB, Pissis P, et al. . Role of oxidative stress and DNA damage in human carcinogenesis. Mutat Res. 2011;711(1-2):193–201. doi: 10.1016/j.mrfmmm.2010.12.016 [DOI] [PubMed] [Google Scholar]
  • 43.Cruz-Gregorio A, Manzo-Merino J, Lizano M.. Cellular redox, cancer and human papillomavirus. Virus Res. 2018;246:35–45. doi: 10.1016/j.virusres.2018.01.003 [DOI] [PubMed] [Google Scholar]
  • 44.Leja-Szpak A, Jaworek J, Pierzchalski P, et al. . Melatonin induces pro-apoptotic signaling pathway in human pancreatic carcinoma cells (PANC-1). J Pineal Res. 2010;49(3):248–255. doi: 10.1111/j.1600-079X.2010.00789.x [DOI] [PubMed] [Google Scholar]
  • 45.Bejarano I, Redondo PC, Espino J, et al. . Melatonin induces mitochondrial-mediated apoptosis in human myeloid HL-60 cells. J Pineal Res. 2009;46(4):392–400. doi: 10.1111/j.1600-079X.2009.00675.x [DOI] [PubMed] [Google Scholar]
  • 46.Casado-Zapico S, Martín V, García-Santos G, et al. . Regulation of the expression of death receptors and their ligands by melatonin in haematological cancer cell lines and in leukaemia cells from patients. J Pineal Res. 2011;50(3):345–355. doi: 10.1111/j.1600-079X.2010.00850.x [DOI] [PubMed] [Google Scholar]
  • 47.Wang Z, Liu Y, Musa AE.. Regulation of cell death mechanisms by melatonin: implications in cancer therapy. Anticancer Agents Med Chem. 2022;22(11):2080–2090. doi: 10.2174/1871520621999211108090712 [DOI] [PubMed] [Google Scholar]
  • 48.Hay N, Sonenberg N.. Upstream and downstream of mTOR. Genes Dev. 2004;18(16):1926–1945. doi: 10.1101/gad.1212704 [DOI] [PubMed] [Google Scholar]
  • 49.Guertin DA, Sabatini DM.. Defining the role of mTOR in cancer. Cancer Cell. 2007;12(1):9–22. doi: 10.1016/j.ccr.2007.05.008 [DOI] [PubMed] [Google Scholar]
  • 50.Manning BD. Balancing Akt with S6K. J Cell Biol. 2004;167(3):399–403. doi: 10.1083/jcb.200408161 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Xu F, Na L, Li Y, et al. . RETRACTED ARTICLE: roles of the PI3K/AKT/mTOR signalling pathways in neurodegenerative diseases and tumours. Cell Biosci. 2020;10(1):54. doi: 10.1186/s13578-020-00416-0 [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  • 52.Yang Y, Li S, Wang Y, et al. . Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective. Signal Transduct Target Ther. 2022;7(1):329. doi: 10.1038/s41392-022-01168-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Seely D, Wu P, Fritz H, et al. . Melatonin as adjuvant cancer care With and without chemotherapy. Integr Cancer Ther. 2012;11(4):293–303. doi: 10.1177/1534735411425484 [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplemental Material
Click here for additional data file. (1.1MB, tif)
Supplemental Material
Click here for additional data file. (1.5MB, tif)
Supplemental Material
Click here for additional data file. (3.4MB, tif)

Data Availability Statement

The data and materials during the current study are available from the corresponding author on reasonable request.

Articles from Redox Report : Communications in Free Radical Research are provided here courtesy of Taylor & Francis

RESOURCES